• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Pharmaceutical Company to Pay $95M to Settle Allegations of Improper Drug Promotion

Article

Boehringer Ingelheim Pharmaceuticals Inc. will pay $95 million to settle allegations that the company promoted three drugs for uses that were not medically accepted, the government announced Thursday.

The Justice Department said the three are the stroke-prevention drug Aggrenox, the chronic obstructive pulmonary disease drug Combivent and the high-blood-pressure drug Micardis.

Read the full story: http://wapo.st/R32A1a

Source: The Washington Post

Related Videos
A new study finds law enforcement presence in emergency departments may disrupt care. Lead author Prashasti Bhatnagar discusses policy and training solutions.
Jennifer Snow, MPA, NAMI
Jennifer Snow, MPA, NAMI
Dr Debra Patt
Most employees are unprepared to shop for coverage on their own, underscoring the need for stronger decision tools and consumer protections.
Experts warn that ICHRAs could either stabilize or destabilize the individual market, depending on which workers employers shift into these plans.
Eleanor Perfetto, PhD
Dr Jennifer Graff, Dr Joey Mattinly, and Brian Reid Dr Jennifer Graff and Brian Reid | Background image credit: ipopba - stock.adobe.com
Dr Jennifer Graff and Brian Reid | Background image credit: ipopba - stock.adobe.com
Related Content
Drug pricing | Image Credit: © TarikVision-stock.adobe.com

TrumpRx Launch Brings Savings—and Uncertainty

February 5th 2026
Article

First announced in September 2025, the online platform is set to offer access to prescription medications at steep discounts, with potential savings in the millions.

Read More

Managed Care Cast Square Image

The Orphan Drug Act in the Modern Drug Pricing Era

February 3rd 2026
Podcast

Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges.

Listen

Many solutions to improve disparities in stroke care come down to appropriate tailoring for the target system and community. | Image credit: BJP7images - stock.adobe.com

Closing Gaps in Stroke Care Starts With Defining the US Health Care Safety Net

February 5th 2026
Article

Clearer definitions, tailored programs and policies, and telestroke care could help close rural stroke care disparities.

Read More

Transparency in Coverage Data to Expose Ghost Rates and Hold Payers Accountable: David Muhlestein, PhD

Transparency in Coverage Data to Expose Ghost Rates and Hold Payers Accountable: David Muhlestein, PhD

January 20th 2026
Podcast

David Muhlestein, PhD, breaks down ghost rates, data gaps, and why stronger oversight is needed to make Transparency in Coverage files usable for patients.

Listen

Jesse Dresser, Esq

New Regulations on PBMs Become Law: What This Means for Pharmacies Nationwide—A Q&A With Jesse Dresser, Esq

February 4th 2026
Article

The Consolidated Appropriations Act of 2026 features new language that could change the way that pharmacy benefit managers (PBMs) operate in the US.

Read More

AJMC original research policy

Increased Payments to Medicare Advantage Plans for Dually Eligible Beneficiaries

February 4th 2026
Article

Increasing Medicare Advantage payments for full Medicaid enrollees was not associated with meaningful changes in inpatient or nursing home use.

Read More

© 2026 MJH Life Sciences
AJMC®
All rights reserved.